Welcome to EverybodyWiki ! Nuvola apps kgpg.png Sign in or create an account to improve, watchlist or create an article like a company page or a bio (yours ?)...

Buspirone/L-DOPA/carbidopa

From EverybodyWiki Bios & Wiki
Jump to navigation Jump to search






buspirone/L-DOPA/carbidopa
Spinalon
Combination of
buspironeserotonin receptor agonist
L-DOPAnucleoside analog reverse transcriptase inhibitor
carbidopadecarboxylase inhibitor
Clinical data
Trade namesSpinalon
Routes of
administration
By mouth
Identifiers
ChemSpider
  • none
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}

The drug combination Buspirone/L-DOPA/carbidopa (trade name Spinalon) is an experimental tri-therapy for the the treatment of chronic spinal cord injury. It is a proprietary fixed-dose combination product discovered by Prof Dr Pierre A. Guertin in 2005 [1]that is being developed clinically since 2012 as an activator of the central pattern generator for locomotion in patients with paraplegia or tetraplegia.

It is not yet approved by the Food and Drug Administration and the European Medicines Agency for use in the United States and Europe.

Two clinical trials are registered on clinicaltrials.com:

In 2017, Nordic Life Science Pipeline and Prof Dr Pierre A. Guertin found no evidence of safety concerns below the maximum tolerated dose following a single administration of buspirone/L-DOPA/carbidopa in forty-five volunteers suffering a chronic spinal cord injury classified as complete (AIS A) or motor-complete (AIS B)(NCT01484184). Some locomotor-like activity in the legs of those who received the experimental therapy, but not in those who received a placebo, was also reported.[2]

In 2019, Jocelyne Bloch from the Centre Hospitalier Universitaire Vaudois announced a clinical study aimed at examining the safety and preliminary efficacy of buspirone/L-DOPA/carbidopa in volunteers with chronic spinal cord injuries (NCT04052776) as a complementary approach to epidural stimulation being developed for commercial purposes by Grégoire Courtine, the chief scientific officer of GTX Medical.[3]

Note[edit | edit source]

The clinical development of buspirone/L-DOPA/carbidopa in Switzerland by the co-founder of GTX Medical has not obtained legal authorizations nor licensing agreements from the inventor and/or the licensor.[4]

References[edit | edit source]

External links[edit | edit source]

Template:Antiparkinson

Template:Amino acids

Template:Dopaminergics

Category:Antidepressants Category:Anxiolytics Category:5-HT1A agonists Category:Alpha-2 blockers Category:Amino acids Category:Catecholamines Category:Hydrazines Category:AAAD inhibitors Category:Antiparkinsonian agents Category:Peripherally selective drugs Category:Prodrugs


Others articles of the Topic Canada : Canadian Centre for Alternatives to Animal Methods, Canada, List of archives in Canada, Johnny Washbrook, Truxx Police Raid, Tygamo, Gillian Jerome


This article "Buspirone/L-DOPA/carbidopa" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Buspirone/L-DOPA/carbidopa. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.



Compte Twitter EverybodyWiki Follow us on https://twitter.com/EverybodyWiki !